Incidental brain cavernomas

Information leaflet for people who do not have symptoms from their brain cavernoma

Cavernoma Alliance UK
Helping the Cavernoma Community

Website: www.cavernoma.org.uk
E-mail: info@cavernoma.org.uk
Registered charity number: 1114145
Who is this leaflet for?

This leaflet is for people affected by a brain cavernoma, which is also known as a ‘cavernous angioma’, ‘cavernous haemangioma’, or ‘cavernous malformation’.

In particular, this leaflet is for people who have a brain cavernoma and:

• do not have symptoms; or

• have symptoms which are not thought to be caused by the cavernoma.

Another way of saying that a brain cavernoma has not caused symptoms is to call it ‘asymptomatic’ or ‘incidental’. (The word ‘symptomatic’ is used to refer to a brain cavernoma which has caused symptoms.) These are terms often used by doctors, and they are used throughout this leaflet.

There are other leaflets in the Cavernoma Alliance UK series:

• one for people who have symptoms due to their brain cavernoma; and

• another for people concerned about the genetic causes of brain cavernomas and whether they run in families.

Picture of the lobes and hemispheres of the brain, and the brainstem (labelled).
What are brain cavernomas?

Cavernomas are clusters of abnormal blood vessels. Cavernomas are found in the brain, brainstem, spinal cord and, rarely, in other areas of the body.

Cavernomas look like raspberries. They are made up of abnormal blood vessels through which blood flows slowly - these are the caverns that give the condition its name. The cells that line these caverns sometimes ooze small amounts of blood into surrounding brain tissue, which sometimes causes symptoms.

Cavernomas can get bigger, but this growth is not cancerous and they do not spread to other areas of the body. Most people with the condition only have one cavernoma. Some people have more than one cavernoma, and these people sometimes develop new cavernomas over time.
How are cavernomas diagnosed?

Cavernomas have been known about since the middle of the 19th century, when they were seen by pathologists examining brains under the microscope.

Magnetic resonance imaging (MRI) is the most accurate test and provides pictures of brain cavernomas. Computed tomography (CT) scans and angiograms cannot be relied upon to show up cavernomas. Doctors only began to see how common cavernomas were when the MRI test was first developed in the 1980s. Before the MRI test was available, symptoms of brain cavernomas were sometimes missed, or mistaken for symptoms of other neurological conditions, such as multiple sclerosis. Even now, some people with a brain cavernoma wonder if they might have been diagnosed earlier if they had had an MRI test to investigate neurological symptoms that they had in the past.
What causes brain cavernomas?

In most cases, it’s impossible to know what caused a brain cavernoma, but there are two recognised causes.

Radiation treatment

Radiation is used to treat a variety of medical conditions. During radiation treatment, a patient’s brain may be exposed to radiation. Some of these people are later found to have a brain cavernoma. If these people have never had an MRI scan in the past, it is impossible to be sure whether the radiation had anything to do with the brain cavernoma developing. Even for patients who have had an MRI scan in the past, the age of the machine and the types of pictures taken during the scan may explain why a cavernoma was never found. However, for a few people who have had an MRI scan before receiving radiation treatment, and another MRI scan later on that identifies a brain cavernoma, it is possible that the radiation may have caused the cavernoma.

Genes

In fewer than half of the people affected by brain cavernomas, there is likely to be a genetic cause. Some people have more than one cavernoma, or may develop more than one cavernoma over time. In these cases there may be a genetic cause. These issues are discussed in further detail in the ‘Information leaflet for people concerned about genetic causes of brain cavernomas’.

How common are brain cavernomas?

Brain cavernomas are quite common. Studies into the results of MRI scans on people who had no symptoms have revealed that approximately one person in every 600 has an asymptomatic brain cavernoma. This means that in the United Kingdom there are roughly 90,000 people with an asymptomatic brain cavernoma - enough to fill Wembley Stadium.
People who experience symptoms from a brain cavernoma are much rarer. A modern study based on the entire population of Scotland has found that, each year, one person out of every 400,000 is diagnosed with a **symptomatic** brain cavernoma for the first time in their life.

Given that there are roughly 90,000 people living in the United Kingdom with an **asymptomatic** cavernoma, this suggests that most people with an **asymptomatic** brain cavernoma continue to be symptom-free in any one year. We do not know the risks an asymptomatic brain cavernoma has over a person’s lifetime.

### Symptoms

The symptoms that a cavernoma might cause depend on where it is in the brain.

Cavernomas near the surface of the ‘hemispheres’ or ‘lobes’ of the brain can cause **epileptic seizures**.

Cavernomas can cause **neurological deficits** in any area of the brain. The most common symptoms of neurological deficit are dizziness, numbness, weakness, disturbed vision, speech difficulty, problems swallowing, and unsteadiness. The type and combination of neurological deficits caused by a cavernoma depend on where exactly in the brain the cavernoma is.

These neurological deficits are sometimes caused by bleeding from the cavernoma, known as ‘haemorrhage’. If a cavernoma bleeds, usually only a small amount of blood oozes from it (half a teaspoonful on average), so cavernoma bleeds rarely cause death or severe disability. In fact, bleeding from a cavernoma sometimes causes no symptoms at all. Brain scans can find new bleeding, but this can only be done accurately by a CT scan within 7 to 10 days after the symptoms began, or by having an MRI scan within two months after the symptoms began.
Some people affected by cavernomas also experience problems with memory, attention, concentration, energy levels, and mood. These symptoms can have a variety of causes, not necessarily the cavernoma.

In the study based on the Scottish population, half (50%) of the people had no symptoms when they were first diagnosed with their brain cavernoma. The symptoms affecting the others were as follows.

- 15% of people had one or more epileptic seizure
- 8% of people had a brain haemorrhage
- 27% of people had neurological deficits, without a haemorrhage showing up on the pictures of their brain

**What is the risk of developing symptoms?**

A few research studies provide information about the outlook (sometimes called ‘prognosis’) for people with asymptomatic brain cavernomas. So far, most of these studies have only involved people attending neurosurgery units, so they do not represent the entire population. Another problem is that the average follow-up period in these studies has been no more than five years. This limits the amount that anyone can know about what will happen in the long term.

Two studies (by Dr Kondziolka and Dr Aiba in the ‘Journal of Neurosurgery’ in 1995) described the outlook for two groups of people - those who had never had a haemorrhage, and those who had. For people who had never had a haemorrhage from their brain cavernoma, bleeding seemed to affect only one in 200 people (0.5%) each year. The risk of future bleeding appeared to be higher for people who first came for medical attention after a brain haemorrhage.
Treatment

Medication is available to treat seizures caused by cavernomas. Other symptoms, such as headaches, can also be treated with medication. The main ways used to try to stop cavernomas bleeding are **neurosurgery** and **stereotactic radiotherapy**.

**Neurosurgery** involves an operation under general anaesthetic. In this operation, the skull is penetrated (called a ‘craniotomy’) and the cavernoma is removed. The method used and the risks involved depend on where the cavernoma is in the brain. Surgery for cavernomas has been made safer using the operating microscope (called ‘microsurgery’). Brain scanning during the operation allows surgeons to reach cavernomas with as little disruption to the normal brain tissue as possible. This procedure is sometimes known as ‘image-guided surgical navigation’ or ‘computer-assisted or frameless stereotaxy’.

[Image: Neurosurgery being performed in an operating theatre.]
Stereotactic radiotherapy involves beams of radiation being targeted at a brain cavernoma from many different points around the head. The radiotherapy beams are targeted very accurately, so it is important that the head does not move while a patient is being treated. Various techniques are used to keep the head still, such as the head frame shown in the picture above. When radiotherapy is given as a one-off treatment, it is sometimes called ‘radiosurgery’. Unlike brain surgery, ‘radiosurgery’ does not involve a general anaesthetic or an operation. Stereotactic radiotherapy is usually carried out to treat cavernomas in regions where brain surgery would be too dangerous. Whether or not stereotactic radiotherapy helps is uncertain.

The main consideration for someone with an asymptomatic cavernoma is whether or not to have treatment. This involves weighing up the risks of leaving the cavernoma alone (one in 200 risk of haemorrhage each year) against the risks of treating it. You should talk to your doctor about your cavernoma before making this decision. Most doctors and patients follow a ‘wait and see’ approach for asymptomatic cavernomas.
Some people ask whether they can have their cavernoma ‘monitored’ by going to clinic appointments and having repeated brain scans. This can be useful when there is any uncertainty about the diagnosis of a cavernoma. However, when diagnosis is certain, no features on a brain scan (such as signs that a cavernoma has grown) are known to show that the risk of bleeding would be higher. For most people, clear information from a doctor, and a clear discussion about whether or not to treat the cavernoma, is probably enough.

**What is still not known about brain cavernomas?**

As you can tell from reading this leaflet, there are still many important questions about cavernomas which we do not yet have answers to. For this reason, you may be asked to take part in research studies.

- We know of three genes that can cause certain types of cavernomas. If you want more information about these, please read the ‘Genetics of brain cavernomas’ leaflet. However, we still don’t know how cavernomas are formed, which is why researchers may want to study the genetic code (DNA) in a blood sample, or brain tissue taken during neurosurgery.

- We know very little about the long-term outlook for people with brain cavernomas, or about what influences the risk of future bleeding.

- For some people and some cavernomas, there is uncertainty about whether to treat them and if so whether to use neurosurgery or stereotactic radiotherapy.

**This leaflet**

This leaflet was written by Rustam Al-Shahi Salman, and reviewed by Neil Kitchen and members of Cavernoma Alliance UK.
How Cavernoma Alliance UK can help

We, Cavernoma Alliance UK, were set up by people affected by brain cavernomas to support sufferers and their families. Our website, www.cavernoma.org.uk, provides information about brain cavernomas, our current members and information about how you can become a member. Along with our parent organisation, Angioma Alliance, based in Virginia, USA, we also provide updates on research.

Mission statement

- To make sure that every person with a brain cavernoma, and their family, has access to clear information about the illness.
- To provide information, through our website, about others affected by brain cavernomas and to provide support.
- To increase awareness of brain cavernomas so that those affected by the condition receive understanding and support.
Medical advisers

Mr Neil Kitchen MD FRCS (SN)
Consultant Neurosurgeon and Associate Clinical Director
at the National Hospital for Neurology and Neurosurgery
Queen Square
London
WC1N 3BG

Dr Rustam Al-Shahi Salman MA PhD FRCP Edin
Honorary Consultant Neurologist
at the Department of Clinical Neurosciences
Western General Hospital
Edinburgh
EH4 2XU

Acknowledgements

We are grateful to Ian Stuart, of Cavernoma Alliance UK,
and also to the British Medical Association for their support.